Like IDH-mutant lower-grade gliomas, more complex multi-gene and multi-CNV prognostic schemes have also been devised for the IDH-mutant GBM category [65,68,69], and large scale studies have shown that there are multiple genetic and epigenetic phenotypes that can result in longer survival in GBM cohorts [113]. This evidence concerns the gene IDH2 and central nervous system cancer.